Abstract
The US surgical hemostat, internal tissue sealant, and adhesion barrier
market was valued at over $1 billion in 2008.
The primary drivers of these three segments will be the growing number of
surgical procedures performed due to the rising incidence of obesity,
diabetes, heart disease, and stroke.
Research Methodology
The following report uses a number of methodologies to gather and present data
and analysis. At the outset, a large survey of secondary sources is conducted.
These sources act as the basis for the primary research stage, which builds
and enhances the quantitative and qualitative attributes of the early research.
Secondary sources include:
- Government Sources:
- Securities and Exchange Commission filings
- Food and Drug Administration and patent filings
- National Center for Health Statistics data
- Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier
Companies:
- Annual reports, product brochures, corporate profiles, etc.
- Internal Databases and Reports:
- Previous reports on similar/related sources
- General Internet Searches, Medical Literature, and Newspaper/Magazine
Searches:
- Identifying various centers of specialization and articles that might
provide leads for primary research.
The secondary research stage builds the foundation for the primary research.
The primary research methodology has four steps:
Step 1: The first step involves an impartial scan of all the
information gathered during the secondary research stage to determine its
utility based on the specific requirements of this report. Each piece of
information is, thus, either discarded or marked as high or low priority. It
is then organized appropriately as determined by the structure and sectioning
of the report.
Step 2: At this stage, early assumptions are formed as to the
implications of the information for the various surgical hemostat, internal
tissue sealant, and adhesion barrier market segments. These assumptions are
then used to determine hypotheses using both inductive and deductive
approaches. On the quantitative front, these hypotheses result in full
historical and projected market data sets (market sizes [units and US$] and
market shares).
Step 3: At this stage, the research is in position for its most
important primary phase - expert interviews. Throughout the secondary
research, industry and medical experts are identified. These experts are now
contacted by telephone and asked to participate in interviews on recent trends
and developments in the industry. Interviews are either conducted at the time
of the initial call or scheduled at the convenience of the expert. Interview
questions are tailored to the expertise of the particular interviewee,
although in most cases, the most important questions are asked of all experts.
The questions are largely based on the assumptions and hypotheses developed in
Step 2, which are then either augmented, discarded, or adjusted, based on the
views and positions put forth. Attempts are made, whenever possible, to
cross�]check the views of various experts against each other and reach
positions of consensus on issues and market numbers.
In addition, a sample of relevant physicians is also surveyed using an online
questionnaire. Physicians are asked to comment on various issues/trend, both
in their own practice and in the overall market. The responses provided are
then used to strengthen or augment the assumptions and hypotheses developed
during the primary research phase.
Step 4: The final stage of primary research involves individual and
group analysis by Millennium Research Group. All research results are assessed
and cross�]checked thoroughly to determine their validity, relevance, and
weight. From this process, qualitative conclusions are reached and data points
finalized.
Table of Contents
TABLE OF CONTENTS
LIST OF EXHIBITS
EXECUTIVE SUMMARY
METHODOLOGY
1.0 US SURGICAL HEMOSTAT, INTERNAL TISSUE SEALANT, AND ADHESION BARRIER MARKET
- 1.1 Market Overview
- 1.2 Market Definitions
- 1.3 Market Analysis
- 1.3.1 Economic Assumptions for the Forecast Period
- 1.3.2 Market Forecast
- 1.3.3 Market Drivers and Limiters
- 1.3.3.1 Market Drivers
- 1.3.3.2 Market Limiters
- 1.4 Competitive Analysis
- King Pharmaceuticals
- ETHICON
- Baxter BioSurgery
- Genzyme Biosurgery
- Pfizer
- Other
2.0 SURGICAL HEMOSTAT MARKET
- 2.1 Market Overview
- 2.2 Product Overview
- 2.3 Market Analysis
- 2.3.1 Thrombin�]Based Hemostat Market
- 2.3.2 Oxidized Regenerated Cellulose�]Based Hemostat Market
- 2.3.3 Gelatin�]Based Hemostat Market
- 2.3.4 Combination Hemostat Market
- 2.3.5 Collagen�]Based Hemostat Market
- 2.3.6 Autologous�]Based Hemostat Market
- 2.3.7 Polysaccharide�]Based Hemostat Market
- 2.3.8 Market Drivers and Limiters
- 2.3.8.1 Market Drivers
- 2.3.8.2 Market Limiters
- 2.3.8.3 Trends and Issues
- 2.4 Competitive Analysis
- 2.4.1 Leading Competitors
- King Pharmaceuticals
- ETHICON
- Baxter BioSurgery
- Pfizer
- Davol
- Orthovita
- ZymoGenetics
- CryoLife
- Integra LifeSciences
- Medafor
- 2.4.2 Emerging Competitors
- Baxter BioSurgery' s Antibiotic Hemostat
- ETHICON and OMRIX Biopharmaceuticals' Fibrin Patch
3.0 INTERNAL TISSUE SEALANT MARKET
- 3.1 Market Overview
- 3.2 Product Overview
- 3.3 Market Analysis
- 3.3.1 Fibrin�]Based Internal Tissue Sealant Market
- 3.3.2 Synthetic�]Based Internal Tissue Sealant Market
- 3.3.3 Protein�]Based Internal Tissue Sealant Market
- 3.3.4 Market Drivers and Limiters
- 3.3.4.1 Market Drivers
- 3.3.4.2 Market Limiters
- 3.3.4.3 Trends and Issues
- 3.4 Competitive Analysis
- 3.4.1 Leading Competitors
- Baxter BioSurgery
- ETHICON
- CryoLife
- Covidien
- 3.4.2 Emerging Competitors
- NeoMend' s ProGEL Series
- Baxter BioSurgery and Nycomed' s TachoSil
- Haemacure' s Hemaseel HMN
- Covidien' s PleuraSeal and DuraSeal Xact
- 3.5 End�]User Survey Results
4.0 ADHESION BARRIER MARKET
- 4.1 Market Overview
- 4.2 Adhesion Formation Overview
- 4.3 Product Overview
- 4.3.1 Films
- 4.3.2 Hydroflotation
- 4.3.3 Gels
- 4.3.4 Soft Tissue Attachment Products
- 4.4 Market Analysis
- 4.4.1 Market Drivers and Limiters
- 4.4.1.1 Market Drivers
- 4.4.1.2 Market Limiters
- 4.5 Competitive Analysis
- 4.5.1 Leading Competitors
- Genzyme Biosurgery
- ETHICON
- Baxter BioSurgery
- MAST Biosurgery
- CryoLife
- 4.5.2 Emerging Competitors
- OMRIX Biopharmaceuticals' Adhexil
- Angiotech Pharmaceuticals' Adhibit
- Integra LifeScience' s DuraGen Plus
- Fidia Advanced Biopolymers and Nordic Pharma Group' s Hyalobarrier Gel
- FzioMed' s Oxiplex/SP Gel
- NeoMend' s ProGEL�]AB
- SyntheMed' s REPEL�]CV Adhesion Barrier
- Covidien' s SprayShield Adhesion Barrier System
- Genzyme Biosurgery' s Sepraspray
- 4.6 End�]User Survey Results
APPENDIX A: MRG ACRONYMS AND INITIALISMS
APPENDIX B: SUPPLEMENTAL EXHIBITS
List of Exhibits
EXECUTIVE SUMMARY
- Exhibit 1: Surgical Hemostat, Internal Tissue Sealant, and Adhesion
Barrier Market, by Segment, US (US$), 2007 - 2013
- Exhibit 2: Surgical Hemostat Market, by Segment, US (US$), 2007 - 2013
- Exhibit 3: Internal Tissue Sealant Market Growth, by Segment, US, 2008 -
2013
- Exhibit 4: Adhesion Barrier Market, US (US$), 2007 - 2013
- Exhibit 5: Leading Competitors in the Surgical Hemostat, Internal Tissue
Sealant, and Adhesion Barrier Market, US, 2008
CHAPTER 1: US SURGICAL HEMOSTAT, INTERNAL TISSUE SEALANT, AND ADHESION BARRIER MARKET
- Exhibit 6: Surgical Hemostat, Internal Tissue Sealant, and Adhesion
Barrier Market, US (US$), 2007 - 2013
- Exhibit 7: Surgical Hemostat, Internal Tissue Sealants, and Adhesion
Barrier Market Segments and Related Products, US, 2008
- Exhibit 8: Surgical Hemostat, Internal Tissue Sealant, and Adhesion
Barrier Market, by Segment, US (US$), 2007 - 2013
- Exhibit 9: Drivers and Limiters of the Surgical Hemostat, Internal Tissue
Sealant, and Adhesion Barrier Market, US
- Exhibit 10: Leading Competitors in the Surgical Hemostat, Internal Tissue
Sealant, and Adhesion Barrier Market, as a % of Total, US, 2008
- Exhibit 11: Leading Competitors in the Surgical Hemostat, Internal Tissue
Sealant, and Adhesion Barrier Market, by Segment, as a % of Total, US, 2008
CHAPTER 2: SURGICAL HEMOSTAT MARKET
- Exhibit 12: Surgical Hemostat Market, US (US$), 2007 - 2013
- Exhibit 13: Coagulation Cascade
- Exhibit 14: Surgical Hemostat Product Overview, US, 2008
- Exhibit 15: Surgical Hemostat Product Overview, US, 2008, Continued
- Exhibit 16: Surgical Hemostat Market, by Segment, US (US$), 2007 - 2013
- Exhibit 17: Surgical Hemostat Market Growth, by Segment, US, 2008 - 2013
- Exhibit 18: Surgical Hemostat Market, by Segment, as a % of Total, US,
2007 - 2013
- Exhibit 19: Thrombin�]Based Surgical Hemostat Market, US (US$), 2007 - 2013
- Exhibit 20: ORC�]Based Surgical Hemostat Market, US (US$), 2007 - 2013
- Exhibit 21: Gelatin�]Based Surgical Hemostat Market, US (US$), 2007 - 2013
- Exhibit 22: Combination Surgical Hemostat Market, US (US$), 2007 - 2013
- Exhibit 23: Collagen�]Based Surgical Hemostat Market, US (US$), 2007 - 2013
- Exhibit 24: Autologous�]Based Surgical Hemostat Market, US (US$), 2007 -
2013
- Exhibit 25: Polysaccharide�]Based Surgical Hemostat Market, US (US$), 2007
- 2013
- Exhibit 26: Drivers and Limiters of the Surgical Hemostat Market, US
- Exhibit 27: Leading Competitors in the Surgical Hemostat Market, as a % of
Total, US, 2008
- Exhibit 28: Leading Competitors in the Surgical Hemostat Market, by
Segment, as a % of Total, US, 2008
CHAPTER 3: INTERNAL TISSUE SEALANT MARKET
- Exhibit 29: Internal Tissue Sealant Market, by Segment, US (US$), 2007 -
2013
- Exhibit 30: Internal Tissue Sealant Product Overview, US, 2008
- Exhibit 31: Internal Tissue Sealant Market, by Segment, US (US$), 2007 -
2013
- Exhibit 32: Fibrin�]Based Internal Tissue Sealant Market, US (US$), 2007 -
2013
- Exhibit 33: Synthetic�]Based Internal Tissue Sealant Market, US (US$), 2007
- 2013
- Exhibit 34: Protein�]Based Internal Tissue Sealant Market, US (US$), 2007 -
2013
- Exhibit 35: Drivers and Limiters of the Internal Tissue Sealant Market, US
- Exhibit 36: Leading Competitors in the Internal Tissue Sealant Market, as
a % of Total, US, 2008
- Exhibit 37: Leading Competitors in the Internal Tissue Sealant Market, by
Segment, as a % of Total, US, 2008
- Exhibit 38: Orthopedic Surgeons' Internal Tissue Sealant Usage, 2008
- Exhibit 39: Orthopedic Surgeons' Internal Tissue Sealant Usage, by
Procedure Type, 2008
- Exhibit 40: Importance of Internal Tissue Sealant FDA Approval for
Orthopedic Surgeons, 2008
CHAPTER 4: ADHESION BARRIER MARKET
- Exhibit 41: Adhesion Barrier Market, US (US$), 2007 - 2013
- Exhibit 42: Adhesion Barrier Products, US, 2008
- Exhibit 43: Select STA Products, US, 2008
- Exhibit 44: Adhesion Barrier Market, US (US$), 2007 - 2013
- Exhibit 45: Drivers and Limiters of the Adhesion Barrier Market, US, 2008
- Exhibit 46: Select List of Adhesion Barrier Clinical Trials, US, 2008
- Exhibit 47: Leading Competitors in the Adhesion Barrier Market, as a % of
Total, US, 2008 (Graphical Format)
- Exhibit 48: Leading Competitors in the Adhesion Barrier Market, as a % of
Total, US, 2008 (Tabular Format)
- Exhibit 49: Orthopedic Surgeon Adhesion Barrier Usage, 2008
- Exhibit 50: Orthopedic Surgeon Adhesion Barrier Usage, by Procedure Type,
2008
- Exhibit 51: Orthopedic Surgeon Adhesion Barrier Usage, by Brand, 2008
- Exhibit 52: Factors Influencing Orthopedic Surgeon Adhesion Barrier
Product Choice, 2008
- Exhibit 53: Orthopedic Surgeon Adhesion Barrier Usage, as a % of Total
Orthopedic Procedures, 2008
- Exhibit 54: Adhesion Complications, as a % of Total, 2008
- Exhibit 55: Importance of Adhesion Barrier FDA Approval for Orthopedic
Surgeons, 2008
APPENDIX B: SUPPLEMENTAL EXHIBITS
- Exhibit 56: Surgical Hemostat, Internal Tissue Sealant, and Adhesion
Barrier Market, by Segment, US (US$), 2007 - 2013 (Detailed Format)
- Exhibit 57: Surgical Hemostat Market, by Segment, US (US$), 2007 - 2013
(Detailed Format)
- Exhibit 58: Internal Tissue Sealant Market Growth, by Segment, US, 2008 -
2013 (Detailed Format)
- Exhibit 59: Adhesion Barrier Market, US (US$), 2007 - 2013 (Detailed
Format)
|
相關報告
|
